Under the collaborative deal, Merck KgaA will provide Erbitux, known generically as cetuximab, in all countries outside of the US and Canada for future registrational study, while Aveo will serve as the study sponsor and will shoulder the costs associated with conducting the trial, according to the statement.
Aveo said that it expects to begin manufacturing of ficlatuzumab clinical supply in Q2, subject to availability of key raw materials and manufacturing supplies, and to initiate a registrational study in the first half of 2023.
Price: 5.15, Change: -0.12, Percent Change: -2.26
|Gain Therapeutics Files $100 Million Mixed Shelf|
|Agnico Eagle Mines to Invest Additional $1.4 Million...|
|Carnival Prices $1 Billion Senior Notes Offering|
|Tencent Music Entertainment, French Embassy in China...|
|Evotec Working With Almirall to Develop New Therapie...|